Phase II Trial of Bevacizumab Combined With Transarterial Chemoembolization (TACE) for Hepatocellular Carcinoma
- Improve median progression-free survival of patients with unresectable hepatocellular
cancer treated with bevacizumab and transarterial chemoembolization therapy.
- Characterize the safety and toxicity of this regimen in these patients.
- Determine the response rate in patients treated with this regimen.
OUTLINE: Patients receive bevacizumab once in weeks 1, 3, and 5. Beginning in week 3,
patients also receive transarterial chemoembolization (TACE) therapy. Treatment repeats
approximately every 8 weeks for up to 3 courses. Patients achieving < 100% necrosis by MRI
after the first course receive 2 additional courses of bevacizumab and TACE.
PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Median progression-free survival
Time to progression of the targeted lesion
Jeffrey F. Geschwind, MD
Sidney Kimmel Comprehensive Cancer Center
United States: Food and Drug Administration
|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||Baltimore, Maryland 21231-2410|